477 related articles for article (PubMed ID: 25560793)
21. Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr Factor VIII:C activity in hemophilic plasma using one-stage clotting assays.
Ingerslev J; Jankowski MA; Weston SB; Charles LA;
J Thromb Haemost; 2004 Apr; 2(4):623-8. PubMed ID: 15102018
[TBL] [Abstract][Full Text] [Related]
22. Discrepancy between the results of one-stage and chromogenic factor VIII: C assays in patients with mild/moderate hemophilia A.
Vosough F; Ahmadinejad M; Toogeh G; Karimi K; Homayoun S; Managhchi MR; Arabkhazaeli A
Blood Coagul Fibrinolysis; 2020 Dec; 31(8):530-535. PubMed ID: 33141777
[TBL] [Abstract][Full Text] [Related]
23. Tyr346-->Cys mutation results in factor VIII:C assay discrepancy and a normal bleeding phenotype - is this mild haemophilia A?
Lyall H; Hill M; Westby J; Grimley C; Dolan G
Haemophilia; 2008 Jan; 14(1):78-80. PubMed ID: 18034822
[TBL] [Abstract][Full Text] [Related]
24. Chromogenic factor VIII activity assay.
Moser KA; Adcock Funk DM
Am J Hematol; 2014 Jul; 89(7):781-4. PubMed ID: 24676945
[TBL] [Abstract][Full Text] [Related]
25. Recombinant to modified factor VIII and factor IX - chromogenic and one-stage assays issues.
Kitchen S; Kershaw G; Tiefenbacher S
Haemophilia; 2016 Jul; 22 Suppl 5():72-7. PubMed ID: 27405680
[TBL] [Abstract][Full Text] [Related]
26. Comparative analysis of chromogenic vs clot.based one stage APTT assay for determination of factor VIII level.
Baig MA; Swamy KB
Indian J Pathol Microbiol; 2021; 64(1):123-127. PubMed ID: 33433421
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of an automated chromogenic assay for Factor VIII clotting activity measurement in patients affected by haemophilia A.
Novembrino C; Boscolo Anzoletti M; Mancuso ME; Shinohara S; Peyvandi F
Haemophilia; 2019 May; 25(3):521-526. PubMed ID: 31044485
[TBL] [Abstract][Full Text] [Related]
28. Does the presence of von Willebrand factor in FVIII-deficient plasma influences the measurement of FVIII inhibitor titres in haemophilia A patients?
Pouplard C; Desconclois C; Sobas F; Aillaud MF; Ternisien C; Caron C
Int J Lab Hematol; 2015 Feb; 37(1):125-32. PubMed ID: 24815078
[TBL] [Abstract][Full Text] [Related]
29. Current laboratory practices in the diagnosis and management of haemophilia: a global assessment.
Kitchen S; Signer-Romero K; Key NS
Haemophilia; 2015 Jul; 21(4):550-7. PubMed ID: 25688866
[TBL] [Abstract][Full Text] [Related]
30. Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization, and recommendations.
Barrowcliffe TW; Raut S; Sands D; Hubbard AR
Semin Thromb Hemost; 2002 Jun; 28(3):247-56. PubMed ID: 12098084
[TBL] [Abstract][Full Text] [Related]
31. Discrepancy between one-stage and chromogenic factor VIII activity assay results can lead to misdiagnosis of haemophilia A phenotype.
Oldenburg J; Pavlova A
Hamostaseologie; 2010 Nov; 30(4):207-11. PubMed ID: 21057709
[TBL] [Abstract][Full Text] [Related]
32. Factor VIII: C (FVIII: C) recovery and half-life after infusion of steam-treated high purity factor VIII concentrate in severe hemophilia A--comparison of one-stage assay, two-stage assay and a chromogenic substrate assay.
Hellstern P; Kiehl R; Miyashita C; Schwerdt H; von Blohn G; Köhler M; Büttner M; Wenzel E
Thromb Haemost; 1986 Dec; 56(3):353-9. PubMed ID: 3105109
[TBL] [Abstract][Full Text] [Related]
33. Analytical variation in factor VIII one-stage and chromogenic assays: Experiences from the ECAT external quality assessment programme.
van Moort I; Meijer P; Priem-Visser D; van Gammeren AJ; Péquériaux NCV; Leebeek FWG; Cnossen MH; de Maat MPM
Haemophilia; 2019 Jan; 25(1):162-169. PubMed ID: 30488994
[TBL] [Abstract][Full Text] [Related]
34. A computer-based model to assess costs associated with the use of factor VIII and factor IX one-stage and chromogenic activity assays.
Kitchen S; Blakemore J; Friedman KD; Hart DP; Ko RH; Perry D; Platton S; Tan-Castillo D; Young G; Luddington RJ
J Thromb Haemost; 2016 Apr; 14(4):757-64. PubMed ID: 26748742
[TBL] [Abstract][Full Text] [Related]
35. Familial discrepancy between the one-stage and two-stage factor VIII methods in a subgroup of patients with haemophilia A.
Duncan EM; Duncan BM; Tunbridge LJ; Lloyd JV
Br J Haematol; 1994 Aug; 87(4):846-8. PubMed ID: 7986726
[TBL] [Abstract][Full Text] [Related]
36. Normalization of factor VIII levels in a patient with mild haemophilia A during a 35-year period.
Mainwaring CJ; Evans J; Chana J; Lewis H
Haemophilia; 2006 Nov; 12(6):668-71. PubMed ID: 17083519
[TBL] [Abstract][Full Text] [Related]
37. Measuring FVIII activity of glycopegylated recombinant factor VIII, N8-GP, with commercially available one-stage clotting and chromogenic assay kits: a two-centre study.
Hillarp A; Bowyer A; Ezban M; Persson P; Kitchen S
Haemophilia; 2017 May; 23(3):458-465. PubMed ID: 28198071
[TBL] [Abstract][Full Text] [Related]
38. Advantages, disadvantages and optimization of one-stage and chromogenic factor activity assays in haemophilia A and B.
Adcock DM; Strandberg K; Shima M; Marlar RA
Int J Lab Hematol; 2018 Dec; 40(6):621-629. PubMed ID: 29979821
[TBL] [Abstract][Full Text] [Related]
39. Impact of variation in reagent combinations for one-stage clotting assay on assay discrepancy in nonsevere haemophilia A.
Suzuki A; Suzuki N; Kanematsu T; Okamoto S; Tamura S; Kikuchi R; Katsumi A; Kiyoi H; Kojima T; Matsushita T
Int J Lab Hematol; 2021 Feb; 43(1):131-138. PubMed ID: 32915508
[TBL] [Abstract][Full Text] [Related]
40. Prevalence, biological phenotype and genotype in moderate/mild hemophilia A with discrepancy between one-stage and chromogenic factor VIII activity.
Trossaërt M; Boisseau P; Quemener A; Sigaud M; Fouassier M; Ternisien C; Lefrançois-Bettembourg A; Tesson C; Thomas C; Bezieau S
J Thromb Haemost; 2011 Mar; 9(3):524-30. PubMed ID: 21166991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
